
The TRANSCEND FL trial showed that treatment with lisocabtagene maraleucel (liso-cel) was effective and safe in patients with relapsed or refractory follicular lymphoma (FL), including those who had high-risk disease in the second-line setting. The findings were published in Nature Medicine.
The study’s lead author, Franck Morschhauser, MD, PhD, of the University of Lille Hospital Center in France, wrote that the participants in this phase II trial represent “a population without an established standard of care and with an unfavorable prognosis.”
Liso-cel is an autologous, CD19-directed chimeric antigen receptor T-cell therapy, and TRANSCEND FL evaluated its use for relapsed or refractory FL. The study cohort comprised patients with disease that had progressed within 24 months of diagnosis despite anti-CD20 antibody plus alkylator management received within six months of diagnosis.
At data cutoff, the study involved 130 patients who received liso-cel and had a median follow-up of 18.9 months. The authors reported that the study’s primary and key secondary endpoints of overall response rate (ORR) and complete response (CR) rate were both met.
Among the 23 patients who received liso-cel as second-line management for FL, the ORR was 96% and all responders achieved CR. Among the 101 patients who received liso-cel as third-line or later management, the ORR was 97% and the CR rate was 94%.
Regarding safety, cytokine release syndrome occurred in 58% of patients, with 1% being grade 3 or higher. Neurological events occurred in 15% of patients, with 2% being grade 3 or higher.
“Results from this study support liso-cel as a potential therapeutic option in patients with relapsed or refractory [FL], including second-line [FL],” Dr. Morschhauser and colleagues concluded.
Reference
Morschhauser F, Dahiya S, Palomba ML, et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024;30(8):2199-2207. doi:10.1038/s41591-024-02986-9. Published correction appears in Nat Med. 2024;30(8):2374. doi:10.1038/s41591-024-03175-4